Market Overview:
The United States hospital acquired disease testing market size reached US$ 4,405.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 15,207.8 Million by 2032, exhibiting a growth rate (CAGR) of 14.32% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year
|
2023 |
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023 |
US$ 4,405.1 Million |
Market Forecast in 2032 |
US$ 15,207.8 Million |
Market Growth Rate (2024-2032) |
14.32% |
Hospital-acquired diseases (HADs) are infections acquired during hospital visits or stays. They are commonly known as nosocomial infections and are caused by bacterial, fungal and viral pathogens. Some of the commonly used HAD testing techniques include the complete blood count (CBC) test, erythrocyte sedimentation rate (ESR) test, urinalysis and analysis of the infected area, blood, urine and other body fluids. These techniques assist in the diagnosis of conditions such as urinary tract infections (UTI), surgical site infections (SSI) and hospital-acquired pneumonia (HAP).
The increasing prevalence of hospital acquired infections (HAIs) and diseases in the United States is one of the key factors driving the growth of the market. Furthermore, the increasing awareness regarding the benefits of the early detection of these diseases is providing a boost to the market growth. Healthcare providers are also emphasizing on maintaining adequate hygiene in hospitals, clinics and other healthcare centers to minimize the risks of HADs. Additionally, various technological innovations, such as the development of microarrays, polymerase chain reaction (PCR), solid phase hybridization and real-time location systems (RTLSs) for preventing and monitoring HAIs, are contributing to the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the United States hospital acquired disease testing market report, along with forecasts at the country and regional levels from 2024-2032. Our report has categorized the market based on indication.
Breakup by Indication:
- UTI (Urinary Tract Infection)
- SSI (Surgical Site Infection)
- Pneumonia
- Bloodstream Infections
- MRSA (Methicillin-Resistant Staphylococcus Aureus)
- Others
Breakup by Region:
- Northeast
- Midwest
- South
- West
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Million |
Segment Coverage |
Indication, Region |
Region Covered |
Northeast, Midwest, South, West |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3699
Five User License: US$ 4699
Corporate License: US$ 5699 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the United States hospital acquired disease testing market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the United States hospital acquired disease testing market?
- What are the key regional markets?
- What is the breakup of the market based on the indication?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the United States hospital acquired disease testing market and who are the key players?
- What is the degree of competition in the industry?